Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Bayer
Woman and Man
Between 18 years
and 99 years
Bayer
Update Il y a 4 ans
CONSIGN : Essai de phase 3b, visant à évaluer la tolérance du régorafénib, chez des patients ayant un cancer colorectal métastatique en rechute. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer la tolérance du régorafénib, chez des patients ayant un cancer colorectal métastatique en rechute après un traitement standard. Les patients recevront des compri...
Country
France
organs
Côlon ou Rectum (colorectal)
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
Estudio multicéntrico, abierto, randomizado, controlado, dos grupos, para evaluar el cumplimiento de la toma diaria en mujeres usuarias de contracepción oral con SHT00186D/BAY 86-5300 (0.02 mg de etinilestradiol como clatrato de betadex, y 3 mg de Drospirenona) en un régimen extendido y flexible, con el apoyo de un dispensador (CADDY) con función de recordatorio, durante 12 meses. (A multicenter, open-label, randomized, controlled, two-arm study to assess compliance with daily tablet intake of women on treatment with the oral contraceptive SH T00186D/BAY 86-5300 (0.02 mg ethinyl estradiol as betadex clathrate and 3 mg drospirenone) in a flexible extended regimen supported by a dispenser (CADDY) with a reminder function over 12 months)
El objetivo del estudio es evaluar el efecto de la función de recordatorio del dispensador en el cumplimientode la toma diaria de comprimidos, durante 12 meses aproximadamente de tratamiento, en muje...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Bayer
Update Il y a 4 ans
Essai de phase 1, en escalade de dose, visant à caractériser la tolérance, la pharmacocinétique et la dose maximale tolérée du BAY 1000394, chez des patients ayant une tumeur maligne avancée. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est de déterminer la tolérance du BAY 1000394, chez des patients ayant une affection maligne avancée. Les patients recevront le BAY 1000394, deux fois par jour, pendant trois ...
Country
France
organs
Tumeurs solides
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman Max 99 years
Bayer Schering Pharma AG
Update Il y a 4 ans
A double-blind, randomized, uncontrolled study to evaluate inhibition of ovulation of two oral estradiol / drospirenone regimens in healthy young female volunteers over a period of 3 treatment cycles
The primary objective of the study is to evaluate the inhibition of ovulation in treatment cycles 2 and 3 after administration of two different (one mono- and one triphasic) 24-day regimens containing...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer Health Care AG
Update Il y a 4 ans
Contrast-Enhanced MRI of the supra-aortic vessels
The primary efficacy evaluation will be based on three primary efficacy variables: • Assessability • Sensitivity • Specificity which will be calculated for both gadobutrol-enhanced MRA and non-co...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Bayer
Update Il y a 4 ans
Étude ROCOCO : étude de phase 1 évaluant la sécurité, la tolérance, la pharmacocinétique, la dose maximale tolérée et/ou la dose recommandée pour la phase 2 du rogaratinib en association avec du copanlisib chez des patients ayant une tumeur solide métastatique ou localement avancé et positive à au moins un sous-type du récepteur FGFR.
Les tumeurs solides peuvent se développer dans n’importe quel tissu : peau, muqueuses, os, organes. Ce sont les plus fréquents puisqu’elles représentent 90% des cancers humains. On distingue 2 types d...
Country
France
organs
Tumeurs solides
Specialty
Immunothérapie - Vaccinothérapie
,
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Man Max 99 years
Bayer Corporation (USA) - provided ciprofloxacin and matching placebo
Update Il y a 4 ans
A multicentre, randomised clinical trial to evaluate the efficacy of oral ciprofloxacin, oral tamsulosin, and the combination of oral ciprofloxacin and oral tamsulosin for the treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Not provided at time of registration
Country
United States
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Bayer Schering Pharma AG
Update Il y a 4 ans
A multi-center, double-blind, randomized, parallel-group study to evaluate cycle control and safety of 6 different regimens of an oral contraceptive containing estradiol and drospirenone in healthy female volunteers aged between 18 and 35 years over 7 cycles
The primary objective of this study is to evaluate and compare the cycle control and bleeding patterns of six different regimens of the combination estradiol and drospirenone over 7 cycles of treatmen...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
A randomised, open-label, multi-center phase II study of first-line treatment with BAY 43-9006 (Sorafenib) versus standard treatment with Interferon alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma
To compare progression-free survival (PFS) of randomised metastatic RCC patients receiving sorafenib 400 mg bid versus standard therapy (interferon alpha-2a) as a first-line therapy.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
Rivaroxaban for the prevention of major cardiovascular events in coronary or peripheral artery disease
Primary objectives for rivaroxaban randomization: •To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a com...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next